These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15534665)

  • 21. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Severe hypertriglyceridemia--an important cause of pancreatitis].
    Graesdal A
    Tidsskr Nor Laegeforen; 2008 May; 128(9):1053-6. PubMed ID: 18451886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hypertriglyceridemia.
    Oh RC; Lanier JB
    Am Fam Physician; 2007 May; 75(9):1365-71. PubMed ID: 17508532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
    Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertriglyceridemia: management of atherogenic dyslipidemia.
    Bersot T; Haffner S; Harris WS; Kellick KA; Morris CM
    J Fam Pract; 2006 Jul; 55(7):S1-8. PubMed ID: 16822443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease.
    Badawy O; Wierzbicki AS; Hilton R
    Int J Clin Pract; 2003 Apr; 57(3):249-51. PubMed ID: 12723736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
    Malloy MJ; Kane JP
    Adv Intern Med; 2001; 47():111-36. PubMed ID: 11795072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hypertricglyceridemia: prognostic impact and treatment options].
    Custodis F; Laufs U
    Dtsch Med Wochenschr; 2011 Jul; 136(30):1533-42. PubMed ID: 21789752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
    Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL;
    Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.